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Nephritic factors comprise a heterogeneous group of autoantibodies against
neoepitopes generated in the C3 and C5 convertases of the complement system,
causing its dysregulation. Classification of these autoantibodies can be clustered
according to their stabilization of different convertases either from the classical or
alternative pathway. The first nephritic factor described with the capacity to stabilize
C3 convertase of the alternative pathway was C3 nephritic factor (C3NeF). Another
nephritic factor has been characterized by the ability to stabilize C5 convertase of the
alternative pathway (C5NeF). In addition, there are autoantibodies against assembled
C3/C5 convertase of the classical and lectin pathways (C4NeF). These autoantibodies
have been mainly associated with kidney diseases, like C3 glomerulopathy and immune
complex-associated-membranoproliferative glomerulonephritis. Other clinical situations
where these autoantibodies have been observed include infections and autoimmune
disorders such as systemic lupus erythematosus and acquired partial lipodystrophy. C3
hypocomplementemia is a common finding in all patients with nephritic factors. The
methods to measure nephritic factors are not standardized, technically complex, and
lack of an appropriate quality control. This review will be focused in the description of the
mechanism of action of the three known nephritic factors (C3NeF, C4NeF, and C5NeF),
and their association with human diseases. Moreover, we present an overview regarding
the diagnostic tools for its detection, and the main therapeutic approach for the patients
with nephritic factors.
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INTRODUCTION
The complement system is a complex molecular system with fundamental roles in apoptotic cell
clearance, immune complex elimination, defense against infections, and modulation of adaptive
immunity (1). Moreover, complement is capable of distinguishing between self-components and
foreign agents. Through a molecular tagging system, complement labels these foreign agents to
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be eliminated by opsonophagocytosis or by direct cell lysis
(2, 3). The complement cascade is activated by three distinct
mechanisms: the classical pathway (CP), the lectin pathway
(LP) and the alternative pathway (AP) (Figure 1). These three
pathways differ mainly in the initial activation steps, but
all of them converge in the activation of the C3 molecule
through the generation of unstable protease complex, called C3
convertases (1–4).
The activation of CP and LP pathways is triggered by
the binding of antigen–antibody complexes, and through
the recognition of mannose groups on bacterial surfaces,
respectively. After its activation, the resulting multi-molecular
complex C3 convertase (C4b2a), is responsible for cleaved C3
molecule into C3a and C3b (Figure 1) (1). The next step
concludes with the incorporation of C3b molecules to the
C4b2a complex, and the generation of the CP/LP C5 convertase
(C4b2aC3b). Finally, C5 convertase splits C5 into C5a, a pro-
inflammatory anaphylatoxin, and C5b, which incorporates to
the formation of the of the membrane attack complex (MAC
or C5b9), along with C6, C7, C8, and C9, on the cell surface.
Two soluble proteins, called vitronectin and clusterin, regulate
this process, preventing its incorporation into cell membranes
(1–4) (Figure 1).
In contrast to the CP and LP, the AP is initiated by
spontaneous activation of C3 in plasma, which occurs through
the “tick-over” (1, 2). This spontaneous activation results in
the production of a few C3a and C3b molecules. The resulting
C3b molecules can then combine with factor B (FB) to form
the inactive AP pro-C3 convertase (C3bB). Then FB is cleavage
by factor D (FD), generating Ba, which is released from the
complex, and Bb, which remains bound. The assembled C3bBb
complex is considered the functional C3 convertase of the AP,
and is capable of amplifying complement activation by a feedback
mechanisms that generates a large number of C3b molecules
within a short time span (1–4) (Figure 1). There is a complement
positive regulator, called properdin (P), which can bind to the
C3bBb complex inducing an increase of his half-life (1, 2). Such
as happened in CP and LP, generation of the AP C5 convertase
(C3bBbC3b) cleaves C5 and ends in MAC formation (1, 2).
The convertase complexes dissociate spontaneously in a few
minutes, a process that is critical to prevent autologous tissue
injury. To prevent this damage, there is a group of soluble
complement regulatory proteins (Factor H (FH), Factor I (FI)
and C4BP) and membrane proteins (MCP/CD46, DAF/CD55,
CR1/CD35, and CD59) with crucial roles in accelerate C3/C5
convertase dissociation, and/or inactivate C3b by proteolytic
cleavage (4, 5) (Figure 1). A strict control between activation and
regulation is necessary; as otherwise, the situation can result in
the appearance of several diseases. Protein deficiencies or protein
abnormal function due to genetic variations, or the presence
Abbreviations: AP, alternative pathway; CP, classical pathway; LP, lectin pathway;
FB, Factor B; P, Properdin; FH, factor H; FI, Factor I; NF, nephritic factor; C3NeF,
C3 nephritic factor; C4NeF, C4 nephritic factor; C5NeF, C5 nephritic factor; C3G,
C3 glomerulopathy; DDD, dense deposit disease; IC-MPGN, immune complex-
associated membranoproliferative glomerulonephritis; APL, acquired partial
lipodystrophy; SLE, systemic lupus erythematosus; C3GN, C3 glomerulonephritis.
of autoantibodies against complement components, such as
nephritic factors (NFs), are associated with several diseases,
including C3 glomerulopathy (C3G), membranoproliferative
glomerulonephritis (MPGN), acquired partial lipodystrophy
(APL) or Systemic Lupus Erythematosus (SLE) (6–8).
NEPHRITIC FACTORS
C3 and C5 Nephritic Factors
NFs were first described in 1969, based on the observation that
the serum from a patient with MPGN and hypocomplementemia
broke down C3 when it was mixed with normal human serum
(9, 10). The activity of NFs was later attributed to the stabilization
of either cell-bound or fluid phase AP complement convertase
by its incorporation into C3 convertase (C3bBb); therefore,
it was called C3 nephritic factor (C3NeF) (11, 12). After
that, C3NeF was characterized as IgG and IgM autoantibodies
with the capacity to recognize neoepitopes of the assembled
AP C3 convertase (13–18) (Figure 2A). Studies focused to
characterize C3NeF showed that IgG with stabilizing capacity
mostly belonged to IgG1 and IgG3 subclasses (14, 15). Moreover,
the Fab portion of the immunoglobulin retained the majority of
the stabilizing function, although other studies show that the Fc
portion also contributes to its functional activity (18, 19).
Several studies have reported that function of C3NeF is
dependent on the presence of P. These P-dependent C3NeFs
are responsible for activation of the C5 convertase, as reflected
by the reduced levels of terminal complement components, and
higher sC5b-9 complexes (20–23). In contrast, patients with
P-independent C3NeF are characterized by low C3 levels and
normal levels of component of the terminal pathway (22, 23). In
a recent study, Marinozzi et al. have designed a novel functional
assay that allows the identification of patients with autoantibodies
with the ability to stabilize the C5 convertase of the AP, which are
called C5 nephritic factors (C5NeF) (Figure 2B) (24). A review
of previous reports establishes that this autoantibody could be
identical to the P-dependent C3NeF described by Tanuma et al.
(22), Paixão-Cavalcante et al. (25) and in several previous papers
(20, 21). C5NeF has been detected as a unique nephritic factor
(10% of cases) or as coexisting with C3NeF (39% of cases) (24).
This new terminology is useful for distinguishing NFs in relation
to their ability to stabilize C3 or C5 convertases.
All C3NeFs increase the half-life of C3 convertase, because
they interfere with the accelerated decay by FH, DAF, and CR1
(25–28). An interesting study used a combination of ELISA
and western blot assays to show the heterogeneous control of
C3NeF on C3 convertase stabilization against spontaneous and
accelerated decay (29). The authors demonstrated that some
C3NeFs strongly stabilized the C3 convertase by preventing both
spontaneous and FH-mediated decay in the absence of P. Other
C3NeFs, however, need P to prevent C3 convertase dissociation
(29). Regarding their epitope specificity, most C3NeFs recognize
a neoepitope on the assembled C3bBb complex. However,
autoantibodies against C3b and FB have recently been reported in
patients with C3G, and these have the same capacity to increase
the C3 convertase half-life as C3NeF (30–32). The main features
for C3NeF and C5NeF are summarized in Table 1.
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FIGURE 1 | The complement system. The complement system can be activated by three pathways. The classical (CP) and lectin (LP) pathways involve recognition of
target-bound antibody or pathogen-specific carbohydrates by C1q or MBL, respectively. In the alternative pathway (AP), continuous, low-level activation of C3 by
spontaneous hydrolysis of the internal C3 thioester, or C3 cleavage by plasma proteases, generates C3(H2O) or C3b. Activation by any of the three pathways leads to
the generation of C3 convertase complexes (C4b2a in the CP/LP and C3bBb in the AP) that cleave C3 into C3a and C3b. Additionally, the AP C3 convertase can bind
properdin (P), a positive regulator that stabilizes the enzyme, extending its half-life more than 10-fold. The C3b generated can, in turn, forms more AP C3 convertase,
allowing amplification of complement activation. The binding of a new C3b molecule to the C3 convertases creates the C5 convertases (C4b2aC3b or C3bBbC3b),
which cleave C5 into C5a and C5b. C5b then initiates the terminal complement pathway, which eventually leads to the formation of the membrane attack complex
(C5b-9) and lysis of the target cells. Complement activation is controlled at various levels by different soluble and membrane regulatory proteins (indicated within
boxes).
FIGURE 2 | Mechanism of action of nephritic factors. (A) C3NeF binds to a neoepitope on the C3 convertase of the alternative pathway (C3bBb), preventing its
spontaneous and FH-mediated decay, and increasing its half-life and C3 consumption. (B) C5NeF binds to a neoepitope on the C5 convertase of the alternative
pathway in the presence of properdin (P) (C3bBbC3bP), preventing its spontaneous and regulator-mediated decay, and increasing its half-life and C5 consumption.
(C) C4NeF binds to a neoepitope on the C3/C5 convertases of the classical/lectin pathway (C4b2a/C4b2aC3b), preventing its spontaneous and regulator-mediated
decay, and increasing its half-life and C3 consumption. Soluble and membrane complement regulators are indicated within boxes.
C4 Nephritic Factor (C4NeF)
C4NeFs are autoantibodies that recognize and stabilize the CP/LP
C3 convertase (C4b2a) (Figure 2C), increasing its half-life in the
fluid and solid phase from a few minutes to several hours (41–
44). They were first described in 1980 in one patient with post-
infectious glomerulonephritis who had low C3 and C5 levels (41),
and in 2 lupus nephritis patients (42). C4NeFs were detected in a
patient with chronic glomerulonephritis (44), and in two MPGN
patients with very low C3 and C5 levels who also presented
C3NeF autoantibodies (45). Coexistence of both C3NeF and
C4NeF in the same patient was corroborated upon screening of
100 MPGN patients, 10 of whom presented C3NeF and C4NeF,
and reduced C3 and C5 levels (38). The reduced C5 levels
observed in these patients is explained by the additional capacity
of some C4NeFs to stabilize the C5 convertase and prevent its
decay (46).
C4NeFs frequency could be underestimated. As assays for
detecting C4NeFs are similar to the assays for detecting
C3NeFs (see section Clinical Associations), the generation of
C3 activation fragments could be erroneously attributed to the
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TABLE 1 | Specificity and clinical associations of nephritic factors.
Epitope Clinical association (frequency)
C3NeF Neoepitope on
assembled C3
convertase of the AP
(C3bBb)
C3GN (40–50%) and DDD (70–80%)
(7, 24, 25, 33, 34)
IC-MPGN (40–50%) (34, 35)
APL (70-80%) (36, 37)
SLE*
C4NeF Neoepitope on
assembled C3/C5
convertase of the
CP/LP (C4b2a or
C4b2aC3b)
C3G and IC-MPGN (3–9%) (38–40)
SLE*
C5NeF Neoepitope on
assembled C5
convertase of the AP
(C3bBbC3bP)
C3GN (67%) and DDD (33%) (24)
AP, alternative pathway; CP, classical pathway; LP, lectin pathway; C3G, C3
glomerulopathy; DDD, dense deposit disease; IC-MPGN, immune complex-associated
membranoproliferative glomerulonephritis; APL, acquired partial lipodystrophy; SLE,
systemic lupus erythematosus; C3GN, C3 glomerulonephritis
*The frequency of C3NeF and/or C4NeF in SLE has not been thoroughly investigated.
presence of C3NeF instead of C4NeF; to avoid this, data on the
levels of C3, C5 and terminal components in the patient’s plasma
should be known. Thus, C3 levels are lower in C3NeF positive
patients than in C4NeF positive patients, while in C4NeF positive
patients reduced levels of C5 and most terminal complement
components are observed (38).
C4NeFs are most likely of the IgG3 subclass (41). In vitro
studies with patients’ purified IgG have been used to determine
themolecularmechanisms of convertase stabilization by C4NeFs.
Protection against C4BP-mediated decay was observed (47),
and later on confirmed in another study that also showed
increased resistance to spontaneous decay and to the proteolytic
inactivation of C4b within the C4b2a complex (43). Resistance
of C4NeF-C3 convertase to the dissociation induced by CR1
has also been shown (48). C3 and C5 convertases stabilized by
C4NeF are strongly resistant to DAF-mediated decay; however,
neither C3NeF nor C4NeF allow assembly of the C3 convertase
in the presence of DAF (27). A recent study with C4NeFs purified
from C3G patients (39) confirms the increased protection against
C4BP- and CR1-mediated decay, as well as stabilization of the C5
convertase. Therefore, C4NeF seems to be a highly effective shield
against the spontaneous and regulator-induced dissociation of
the CP C3/C5 convertases (Figure 2C). The main features for
C4NeF are summarized in Table 1.
DIAGNOSTIC TOOLS TO DETECT
NEPHRITIC FACTORS
Several methods for the evaluation of NFs have been reported
in the literature. Although the old and very simple methods
based on mixing normal and hypocomplementemic serum
from suspected individuals and the subsequent identification of
complement activation markers are still in use, they appear to
be of low sensitivity; therefore, a number of more sophisticated
protocols have been developed (25). Modern methods are
based on measuring the binding of NFs to the pre-formed
C3 convertase (see section Binding Assays), or measuring
C3/C5 convertase activity in the presence of an NF-suspected
sample (see section Functional Assays) (Figure 3). However, such
methods represent a substantial challenge due to the labile nature
of the C3/C5 convertases, and to a number of situations that
mimic NF activity; like as presence of gain-of-function mutations
in C3 and FB (49, 50). Apparently, detection of NFs remains
problematic, because the 2015 European quality assessment
revealed that only half of the participating laboratories properly
identified C3NeF reference samples (51). Of note, there is no ideal
test capable of covering all difficulties, and both binding assays
and functional assays have advantages and drawbacks. Therefore,
the combination of convertase assays helps not only improving
the specificity of detection but also shedding light on the nature
of NFs.
Binding Assays
Binding assays use convertases reconstituted from purified
components on artificial surfaces such as microplates or
biosensor chips. Identification of the ligand bound to the
convertase complex can give rise to a diagnosis of NF. However,
ligand binding may not have any influence on enzyme function,
and therefore the positive results of binding assays might not be
physiologically relevant. This possibility is reflected by the fact
that a certain portion of C3NeF-positive samples detected by
binding assays were negative in other functional assays, possibly
representing false-positive results (25). However, binding assays
performed on purified convertase components allow study the
kinetics of convertase dissociation, especially when performed
with surface plasmon resonance techniques (52). There are
several procedures described for the detection of C3NeF (53).
Typically, C3b is immobilized on the microplate surface and
then reacted with FB and FD. High yields of microplate-
attached alternative convertase complexes are achieved by the
addition of NiCl2 (53) or NiSO4 (25), which outperforms
magnesium ions normally supporting convertase formation. The
most popular binding assays are enzyme-linked immunosorbent
assays (ELISAs) to detect immunoglobulins bound to preformed
convertase complex (CO-Ig) (Figure 3). However, such assays
might not identify the non-Ig C3 activating factors (54). Another
version of the ELISA-based binding assay, the so-called C3NeF
stabilization (COS) assay, detects plate-bound Bb fragments with
a polyclonal antibody (Figure 3) (25). The COS assay, like assays
detecting convertase-bound Igs, begins with C3b deposition
followed by the addition of test serum or purified Ig fraction
together with FB, FD and optionally, P (COS-P assay) (Figure 3).
Detection of Bb fragments on the plate surface coated with
C3b indicates the presence of complete AP convertase, which
normally decays within minutes when no stabilizing agent is
present. Importantly, experimental data by Paixão-Cavalcante
et al. showed that 36 out of 101 samples collected from patients
with complement-related renal diseases were found to be positive
for C3NeF in a COS-P assay but only 16 out of these 36 were
positive in a COS assay (25). This difference indicates that C3NeF
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FIGURE 3 | Diagnostic tools for the detection of nephritic factors (NFs). The functional activity of C3NeF can be determined through quantifying complement
activation products (mostly C3 fragments) by two-dimensional immunoelectrophoresis, immunofixation electrophoresis or western blotting (A). However, the main
tools for the detection of NFs activity are the hemolytic assays, which measure the lysis of sheep (SE)/rabbit erythrocytes (RE) (B). In these assays, purified
complement components are added to perform convertases on the surface SE sensitized with anti-sheep antibodies (EA). Later, purified FB, FD and P are added to
form specifically alternative pathway convertase. Other assays are developed using whole serum (patient’s serum and normal human serum (NHS), in ratio 1: 1) to
generate convertases on the SE or RE surface. Considering that RE could be lysed by human serum, terminal pathway needs to be blocked using C5 blockers (OmCI
or eculizumab). Another option to measure NF activity is through the quantification of anaphylatoxins, C3a and C5a (C). There are binding assays to detect C3NeF
based on enzyme-linked immunosorbent assays (ELISA) that detect immunoglobulins bound to the preformed convertase complex (CO-Ig). Other versions of the
ELISA-based binding assay are the so-called C3NeF stabilization assays, which use a polyclonal antibody to detect plate-bound Bb fragment generated either in the
absence (COS assay) or in the presence (COS-P assay) of P.
are very heterogeneous with regard to binding sites and that P
might play a role in AP convertase stabilization by C3NeF.
Functional Assays
Analysis of C3 Breakdown Products
As mentioned earlier, the first functional assays relied on
mixing control and NF-suspected sera, and further analysis
of complement activation products (mostly C3 fragments) by
two-dimensional immunoelectrophoresis (55), immunofixation
electrophoresis (56) or western blotting (25) (Figure 3). The
idea behind these assays is that the spontaneous breakdown of
C3 that normally initiates the AP is augmented by convertase
stabilization by NFs. Therefore, 3 h of incubation at 37◦C is
enough time to observe substantial C3 cleavage in samples
containing C3NeF in contrast to samples containing normal
serum only. Of note, all samples found positive in assays
measuring C3 breakdown products were also positive in COS-
P binding assays (however, COS-P assays detected more positive
samples) but some of them were negative in CO-Ig binding
assays (25). A possible explanation is that COS and COS-P
assays can be considered quasi-functional assays that detect
protein fragments resulting from convertase activity. The same
applies to assays performed with surface plasmon resonance
techniques, which monitor the association and dissociation of
convertase complexes.
Hemolytic Assays
Many functional convertase assays measuring the effect of
enzymatic activity use red blood cells because they provide an
easy readout: the release of hemoglobin, which can be easily
quantified by measuring absorbance at 405–420 nm (Figure 3).
The general rule is that after deposition of active convertases,
the addition of a heterologous serum (e.g., guinea pig serum,
which is capable of MAC formation on human convertases but
offers limited activity of regulatory proteins) or purified terminal
pathway components diluted in ethylene-diamine-tetraacetic
acid (EDTA)-gelatin veronal buffer will generate lytic sites.
Chelating of magnesium and calcium by EDTA avoids assembly
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of new convertases but does not influence MAC formation on
a platform of already assembled convertases. Depending on the
version, these functional assays can analyze purified components
(e.g., protein A/protein G-purified Ig fraction from individuals
suspected for NFs, which is added during or just after the
convertase formation step) or whole serum. The use of whole
serummay introduce confounding factors like soluble convertase
inhibitors, which can be present at different concentration in
particular individuals. Nonetheless, the presence of NF usually
prevents activity of such inhibitors and should be manifested in
prolonged convertase half-life. Therefore, the assay performed
with whole serum as an analyte is a rather quick screening
method only showing probability of NF presence, which should
be further confirmed by testing of purified Ig fraction.
Assays using C3/C5 convertases assembled from purified
components
The stepwise building of convertase complex on the surface
of sheep erythrocytes enables the analysis of CP/LP and AP
enzymes. In the first step, C1 complex is deposited followed
by C4, which binds covalently to the membrane. Then, C2
together with the test sample is added, and after incubation the
mixture is washed and replaced by guinea pig or rat serum (fully
compatible with human serum but of higher terminal pathway
efficacy) in EDTA-buffer (39, 46, 57, 58). This experimental
design enables the measurement of CP/LP C3 convertase activity,
whereas the addition of C3 molecules together with C2 enables
the formation of C5 convertase. CP/LP C5 convertase is also
formed to deposit AP convertases. Covalent binding of C3b is
followed by the removal of noncovalently bound C1 and C2 by
prolonged incubation in 10mM EDTA-buffer. Later, FB, FD, and
P are added, thus forming AP convertases (57, 58). After this
step, purified Igs purified from patients are used to evaluate NF
capacity. This method cannot ensure a clear distinction between
C3 and C5 AP convertase activity, but such attempts can be
performed either by titrating C3 and thus manipulating C3b
density (59) or by developing lytic sites by mixing purified C5-C9
components± C3 (57). An alternative method of C3b deposition
is incubation of erythrocytes with C3 and trypsin at 22◦C (59, 60).
Functional assays with whole serum
The stepwise formation of convertases from isolated complement
components allows the analysis of the purified Ig fraction from
an NF-suspected individual, but it also presents certain
limitations. A major drawback is the inability to reproduce
the physiological serum context, where many proteins
are potentially capable of influencing convertases’ activity.
Therefore, convertase-interacting components identified in
assays based on purified complement proteins might not
accurately reflect physiological interactions. Convertase assays
performed with whole serum are based on a similar design,
i.e., convertase formation on erythrocytes as the first step,
and generation of lytic sites by addition of EDTA-serum
in the second step. Sheep erythrocytes sensitized with anti-
sheep antibodies (e.g., amboceptor) offer the possibility of
forming CP/LP C3 convertase (C4b2a) when erythrocytes
are incubated in C3-depleted serum (61). The complement
cascade proceeds up to the step of C3 convertase but no
further. Similarly, incubation in C5-depleted serum results in
the formation of C5 CP/LP convertase C4b2aC3b (61). The
high efficacy of CP/LP convertase formation on sensitized
sheep erythrocytes enables the application of low serum
concentrations (<1%), excluding the possibility of AP
convertase formation, which demands a higher (2%) serum
content. Rabbit erythrocytes, which spontaneously activate
AP when incubated with human serum, are used for assays of
AP convertase. However, this method is unable to distinguish
between C3 and C5 convertases, given that both of them
contain C3b. Carrying out the reaction in ethylene glycol-bis(β-
aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA)-buffer
excludes the activation of CP/LP, which demands calcium and
magnesium, whereas AP only requires magnesium (not affected
by EGTA).
The idea of blocking the complement cascade at the level of
C5 gives rise to another version of functional convertase assays
that can be performed in whole serum, e.g., collected directly
from the patient. To this end, C5 inhibitors such as eculizumab
or Ornithodoros moubata complement inhibitor (OmCI) have
been successfully applied (49). Testing whole serum excludes
a precise diagnosis of NFs, but it is a useful screening test
for searching any components that interfere with convertase
activity and/or stability. Recently, this assay was successfully
validated in a cohort of C3G patients. The results revealed
that the combined analysis of patient’s serum and purified
Ig fraction properly distinguished patients with convertase-
stabilizing activity localized in the Ig fraction (with positive
readouts in serum and Ig fraction) from those with familial
aHUS caused by gain-of-function mutations in complement
components (positive readout only in serum) (62). This method
was also successfully applied to diagnose C4NeF in a C3G patient
who did not present any other abnormalities in complement
proteins and was negative for C3NeF and other autoantibodies
against AP components (40). Technically, convertase assays with
whole patient’s serum demand mixing of patient’s sample with
normal human serum, usually in 1:1 ratio. Since NF presence
is often associated with hypocomplementemia, low content of
complement components in unmixed patient’s serum results in
low amplitude and delayed peak of convertase activity, which
may mask convertase-stabilizing effect. However, addition of
normal human serum as a source of complement components
to NF-containing, hypocomplementemic serum, allows readouts
for convertases of prolonged / enhanced activity (49). It is
worth mentioning that the first hemolysis-based, two-step assay
intended to diagnose C3NeF in patient serum was described
more than 30 years ago (63) and was later modified (64, 65).
The so-called Rother assay is still in use in some diagnostic
laboratories but it often gives inconclusive results. This test
uses sheep erythrocytes, which are not an optimal target for
AP activation. The kinetics of this process are slower than for
analogous AP activation on rabbit erythrocytes, and therefore it
is theoretically possible to extract a time point when convertases
are already formed but MAC is not yet assembled. In practice,
choosing such a time point is arbitrary and will not necessarily
work for every individual serum tested. Indeed, many samples
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cause hemolysis in the first step of this assay, and thus preclude a
reliable diagnosis.
An emerging problem for functional convertase assays in
detecting NFs is the lack of widely available standards. The most
commonly used strategy is to compare results obtained with the
results of a reference serum (a highly-positive sample), which has
limited availability. This problem is combined with the batch-
to-batch differences in erythrocytes, giving rise to high inter-
assay variability, and the inability to strictly compare the values
obtained in two different laboratories. A possible solution is to
use gain-of-function mutants of convertase-forming proteins,
which mimic the effect of NFs. For example, a recombinant
FB K323E mutant has been proposed as a reference for C3NeF
detection (50).
Generation of C3a and C5a by Preformed
C3/C5 Convertases
Another option for measuring convertase activity is to quantify
the anaphylatoxins C3a and C5a, which are products of C3
and C5 cleavage by the C3 and C5 convertases, respectively.
In this assays, the formation of convertases from purified
complement components takes place on the surface of beads.
Thereafter, the substrates (C3 or C5) are added together
with the tested sample, and the supernatant containing
anaphylatoxins is transferred to a culture of reporter cells,
previously transfected with C3aR or C5aR. The intensity of
the readout in calcium mobilization assays is proportional to
the amount of C3a and C5a generated; therefore, this assay
enables to distinguish between C3 and C5 convertase activities
(66). Such method, not yet demonstrated usefulness for NF
detection would be compatible with purified Ig fraction as
an analyte.
CLINICAL ASSOCIATIONS
C3 Glomerulopathy/Membranoproliferative
Glomerulonephritis
C3G is a recently adopted term to refer to a few rare
kidney diseases caused by dysregulation of the AP, and
characterized by significant C3 deposition in the glomeruli
with minimal or no presence of immunoglobulins (67–69).
Although there is no a specific histological pattern, most of
the C3G cases correspond to some types of the previously
denominated MPGN. C3G is classified into Dense Deposit
Disease (DDD) and C3 glomerulonephritis (C3GN) on the
basis of the electron microscopy findings. Dense Deposit
Disease is characterized by distinctive highly electron-dense
intermembranous deposits whereas C3GN is characterized
by mesangial, intramembranous, subendotelial and sometimes
subepithelial deposits (67–72).
C3NeF has been detected mainly in patients with immune
complex-associated-MPGN (IC-MPGN) (40–50%) and in
patients with C3G (40–80%) (7). Approximately 80% of
patients with DDD and in 40%-50% of patients with C3GN
(51, 72) are positive for C3NeF. Recently, Donadelli et al.
published a study providing an interesting method to detect
and characterize C3NeF in patients with C3G and IC-MPGN
(29). The authors reported that most of the patients with DDD
had C3NeF that stabilized C3 convertase in the absence of
P, while in the remaining patients (C3GN and IC-MPGN)
C3NeF was P-dependent (C5NeF), resulting in both C3 and
C5 convertase dysregulation (29). These results are reliable
with the previous observation that C3NeF targets both C3
and C5 convertases in 67% of patients with C3GN (24),
and that terminal pathway dysregulation is significantly
higher in C3GN than in DDD (24, 29). Moreover, our group
documented that a subset of C3G patients with low P levels
(most of them C3GN) was characterized by C5 consumption
and high sC5b-9 levels in plasma (33). However, although
our results are consistent with the presence of C5NeF, we
could not prove it due to the lack of a specific assay to detect
this autoantibody.
The pathogenic role of C3NeFs in C3G has been debated
for a long time. Although C3NeFs are closely linked with C3G,
they have been detected in healthy individuals, suggesting that
this autoantibody is part of the normal immune repertoire (73,
74). Therefore, a fundamental unanswered question is whether
C3NeF is the cause of the disease, or whether C3NeF is a
consequence of the disease process that then acts exacerbating
the disease pathology (17, 74, 75). Moreover, plasma C3
consumption and disease severity do not always correlate with
the presence and activity of C3NeF (76–78). Autoantibodies
related to complement components, such as anti-FB, anti-
C3b, anti-FH or other autoantibodies (e.g., ANAs, ANCAs or
cryoglobulins) have been detected in smaller percentages of
patients (79). Overall, in the series from Mayo Clinic, 13.4%
of C3G patients were positive for autoantibodies other than
C3NeF (80).
C4NeFs autoantibodies have been mainly found in patients
with MPGN (38, 44, 45, 81). A study in 100 patients with
hypocomplementemic MPGN showed that as many as 19
patients had C4NeF (alone or in combination with C3NeF)
(38). The 10 patients having both C3NeF and C4NeF presented
low C3, C5, and terminal complement component (C6–
C9) levels, as well as massive C3 deposits in the kidneys
by immunofluorescence microscopy; moreover, they presented
therapy-resistant hypocomplementemia, a higher incidence of
nephritic syndrome and a poorer prognosis than patients positive
for only C3NeF or C4NeF. These 10 patients would have been
diagnosed of C3G according to current criteria (70). Another
interesting observation in this study is that one patient was
subsequently C3NeF positive, C3NeF negative, and C4NeF
positive, suggesting than autoantibody specificity can change
along disease evolution.
More recently, a C4NeF that reduced decay of the CP C3 and
C5 convertases was detected in 1 out of 13 C3G patients (40).
The patient had reduced C3 levels, but C4 and FB levels were
normal. C4NeFs have been also found in 4/100 C3GN patients,
and in 1/68 DDD patients, representing 3% of the 168 C3G
patients included in the study (39); 1 of these patients also had
anti-FH autoantibodies, and another patient had C3NeF. The
low frequency of C4NeF-positive patients (3%) in comparison
with C3NeF-positive patients (52%) in this large and well
documented C3G series suggests that the actual contribution
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of C4NeF to the pathogenic mechanism is less relevant than
the contribution of C3NeF, and it could be associated with an
infectious trigger. This possibility is in line with the authors’
observation that kidney biopsies from their C4NeF-positive
patients are suggestive of post-infectious glomerulonephritis
which evolved into C3G.
Acquired Partial Lipodystrophy (APL)
APL or Barraquer-Simons syndrome (ORPHA:79087) is an
ultra-rare disease characterized by progressive loss of adipose
tissue starting from the face and then extend to the neck,
shoulders, upper extremities and then to the thorax. Patients
may accumulate fat excess in the lower extremities after
puberty, especially female patients (36). APL is more frequent
in females than males (4:1) (82). Metabolic syndrome and
its comorbidities are absent or infrequent in this syndrome
(83). However, autoimmune diseases, particularly SLE
and dermatomyositis, have been reported in patients with
APL (36, 84).
Adipsin is an adipokine produced by mature adipocytes
(85). In 1992, White et al. shown that human adipsin was
identical to complement FD and that it major source was located
in the adipose tissue (86). Moreover, adipocytes also express
C3, FB and complement regulators such as P and FH, and
consequently complement is connected to adipocyte biology
(87). Indeed, complement system functions on adipose tissue, as
preadipocyte differentiation and triacylglyceride synthesis, have
been described (88).
C3 hypocomplementemia in relation with the presence of
C3NeF have been reported in almost all patients with APL (82–
84, 89–103). Therefore, as a consequence of the presence of
C3NeF, approximately 20% of patients with APL develop C3G
in a period of 8 years after the onset of lipodystrophy, and
some of them evolve to end-stage renal disease requiring renal
transplantation (83). Although complement dysregulation is a
common mechanism in C3G and APL, the exact mechanism
of fat loss remains unclear (87). There is one experimental
study which described complement-mediated lysis of adipocytes
in vitro by C3NeF (87, 104). However, the proposal fails
to answer the key question of not all patients with C3NeF
develop lipodystrophy.
SLE and Infections
C3NeF have been described in patients with SLE, associated in
most cases with partial lipodystrophy and/or DDD (90, 95, 96,
105–111). However, there are several studies describing patients
with lupus nephritis, complement abnormalities and the presence
of autoantibodies against AP proteins in absence of C3NeF (112–
114). For example, our group published a case of lupus nephritis
with autoantibodies against C3, FB and P, which was negative
for C3NeF (112). Other authors reported that approximately
30% of patients with lupus nephritis were positive for anti-C3
autoantibodies (113). These autoantibodies have a similar effect
as C3NeF, which should be taken into consideration during
the diagnosis.
C3NeFs have been detected in patients with meningococcal
infections, without renal impairment (115–121). By
contrast, there are several cases series of post-streptococcal
acute glomerulonephritis associated with C3NeF
activity (122–125).
C4NeFs have also been found in a few SLE patients (42),
and occasionally following streptococcal (41) or meningococcal
(46) infections. The latter is a peculiar case of a C4NeF
autoantibody that did not provoke a renal phenotype, but it
was found in a patient with severe meningococcal disease.
This C4NeF autoantibody stabilized the C3 and C5 convertases
from the CP and generated C3 deficiency by increased
consumption (46).
DIAGNOSTIC APPROACH TO IDENTIFY
NEPHRITIC FACTORS
Several renal diseases are caused by complement dysregulation,
and while the most common causes of impaired complement
regulation are pathogenic mutations or anti-FH autoantibodies
in atypical hemolytic uremic syndrome (aHUS), in C3G NFs
are the most frequent finding (34, 69). Although definitive
diagnosis should be based on light and electron microscopy
findings of kidney biopsy, some laboratory tests may support
the diagnosis.
After suspicion or definitive diagnosis of C3G, C3NeFs have
to be screened in the first steps, together with serum C3 levels.
Other parameters included in the current laboratory diagnostic
protocol are commented below.
Serum C3 and C4 levels can be measured fast and easily
by automated methods, as nephelometry or turbidimetry, but
normal C3 levels do not exclude NF presence. Complement
activation can also be assessed by measuring C3d, FB, P
and sC5b9, not only to demonstrate AP dysregulation but to
differentiate between C3/C4NeFs and C5NeF (33, 51, 126).
Serum from C3G patients should be screened for
autoantibodies (16), including anti-FH (55, 127, 128), anti-
FB (31, 129), and anti-C3 (32), all of them causing alternative
pathway dysregulation, but the presence of any of these
autoantibodies do not exclude NF existence, as anti-FH
autoantibodies are frequently associated with C3NeF in pediatric
C3G patients (130). FH deficiency is associated with DDD
and C3GN (131, 132), as it leads to totally uncontrolled AP
activation. Besides serum FH levels, a genetic study is necessary
because single point mutations in FH gene causing C3GN have
been described (102, 133).
Genetic screening of AP regulators and convertase
components should be undertaken in a complete complement
study of C3G patients. Common and pathogenic variants
associated with C3G have been described in FH, FI, FB, CD46,
C3 and thrombomodulin genes, influencing on long-term
outcome (5, 34, 35). Again, the presence of any mutation or
variant do not exclude NF existence, as it’s shown in a French
C3G series, where C3NeF was present in 50% of patients carrying
mutations in complement genes (34).
Defective complement regulation has been demonstrated in
C3 and CFB mutations associated with C3G; these mutations
impair C3b inactivation by FI (134) increase convertase
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resistance to dissociation by FH (135), or promote high–affinity
binding of C3 to FB (136).
A genetic and protein approach to study the Factor H-Related
(FHR) proteins is also recommended, as mutations and gene
rearrangements causing FHderegulation have been reported over
the last years in C3G patients (137–143).
MANAGEMENT AND THERAPEUTIC
PERSPECTIVES FOR PATIENTS WITH
NEPHRITIC FACTORS
In the last years, there has been an important progress in
the knowledge about treatments for autoimmune diseases. The
presence of NFs should be considered the main autoimmune
cause of diseases as C3G and IC-MPGN. In most of consensus
reports, the experts indicate that treatment is directed to
improve clinical parameters. However, a specific disease-directed
treatment for patients with NFs has not been established. There
are no randomized trials able to generate therapeutic decisions, so
all current recommendations are based on low-quality evidence
since the patients’ series include a heterogeneous and limited
number of cases. Therapies are divided into common treatments
indicated to all autoimmune diseases and specific complement
blocking drugs:
• Plasma Exchange Therapy/Plasmapheresis: In order to remove
NFs, plasma exchange has been used with irregular efficacy.
A combined treatment based on plasma exchange and
immunosuppressants has proved useful in patients with C3G
positive for C3NeF (144). However, with these results it was
difficult to evaluate the effect of plasma exchange since the
treatments were administered all together. An interesting work
showed that using long-term plasmapheresis removed C3NeF
activity from the serum of patients with DDD (145).
• Immunosuppressive Therapy: These treatments are focused
to limit and/or reduce the production of NFs, and they
have mainly been proved in patients with C3G and MPGN.
The benefit of long-term alternate-day steroid therapy for
idiopathic MPGN has been suggested; however, these studies
include a combination of patients with different types of
MPGN, limiting possible conclusions (75, 146, 147). An
interesting report from the Spanish Group for Glomerular
Disease Study showed the effectiveness of the combination of
mycophenolate mofetil (MMF) and glucocorticoids in patients
with C3GN (148). This study compared the clinical evolution
of three groups of C3GN patients: one without glucocorticoids
treatment, one with glucocorticoids but no MMF and another
one based on MMF plus glucocorticoids. The results showed
that eight out of ten patients with C3NeF (80%) were more
likely to achieve remission with this treatment. However,
this clinical improvement could not be attributed to C3NeF
disappearance because it determination was not performed
in all patients during the whole course of the treatment. A
similar although less impressive response was described in a
large cohort from the Mayo Clinic (80).
• Monoclonal Antibody Therapy: Antibody-producing B cell-
targeted therapies should be effective in patients with
C3NeF, but the data using a monoclonal anti-CD20 antibody
(rituximab) have not been consistent regarding C3NeF activity
and clinical response (149–151). The experience on the use
of rituximab in MPGN, C3GN, and DDD with or without
NFs is limited to case reports and retrospective case series.
Patients with IC-MPGN who were treated with rituximab
showed partial and complete responses in the majorities of
cases, while treatment was not effective in most C3GN and
DDD cases (152).
• Complement Directed Therapies: Complement blocking
agents such as eculizumab (Soliris) have been also
tried in patients with NFs as the only pathogenic cause
or in combination with mutations in complement
components (153, 154). Almost all authors coincide in
that eculizumab therapy should be considered after the failure
of immunosuppressive and plasma exchange treatments to
improve renal function. A large series using eculizumab in
C3G have been published by Le Quintrec et al. from France
(154). Briefly, 23% of their patients had a global clinical
response, while 23% had a partial response and the remaining
54% were nonresponders. The patients with a good clinical
response had lower glomerular filtration, a more rapidly
progressive course and more extracapillary proliferation as
determined by kidney biopsy (154). Parameters including
age, extent of renal fibrosis, nephrotic syndrome, C3
levels, C3NeF activity, sC5b-9 concentration or pathogenic
complement gene variants did not differ between responders
and nonresponders (154). There are several reports that
show that eculizumab may be a specific and useful treatment
in C3NeF-related DDD (103, 151). A potential benefit of
eculizumab treatment was suggested for the five C4NeF-
positive patients described by Zhang et al. (39), who presented
elevated plasma levels of sC5b-9.
New complement modulators targeting C3 convertase activity,
such as soluble CR1 (sCR1), have been proved in sporadic
cases of C3G (155). The in vitro activity of sCR1 prevents
the hemolysis of rabbit erythrocytes caused by C3NeF with
greater effectiveness than FH. The administration of sCR1 to
Cfh–/–/huCR1-Tg mouse resulted in markedly reduction of C3
deposits along the glomerulus. However, C3 staining not changed
before and after treatment in an 8-year-old girl positive for
C3NeF with biopsy-proven DDD although the authors observed
a transient improvement in C3 serum levels and a decreased
of sC5b-9.
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